Loading company…
Axelyf develops RNA medicine technology, including its AXL lipid nanoparticle delivery system for gene therapy applications.
Axelyf, Inc. is a US-based biotech company founded in 2022 in Brookline and based in Chestnut Hill, Massachusetts. Its AXL lipid technology is intended to optimize gene editing and reduce toxicity, and it serves pharmaceutical and biotech companies in gene therapy, mainly in North America and Europe. In July 2025 the company raised USD 4.84 million in seed funding led by new investor Brunnur Ventures, with participation from Silfurberg and Omega Funds.
2 rounds recorded · latest Private placement (Form D), Oct 2026
Sign in to see 2 rounds.
Sign inSign in to see 2 investors.
Sign inSign in to see 1 more people.
Sign inAxelyf, Inc. has no recorded acquisitions.
Add an acquisitionStill private — no exit on record.
Record an exitNo diversity signals recorded yet for Axelyf, Inc..
Add diversity data